Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Cytokinetics chief legal officer sells $794,877 in shares

Cytokinetics chief legal officer sells $794,877 in shares

Cytokinetics Inc. (NASDAQ: CYTK) Chief Legal & Administrative Officer Jeffrey Hessekiel sold 15,106 shares of the company's common stock on November 17, 2026, for a total of $794,877. The shares were sold at $52.62 per share, and the sale was intended to cover tax withholding obligations related to the vesting and settlement of restricted stock units.

This transaction was mandated by the company and not a discretionary decision made by Hessekiel. After the sale, Hessekiel owned 92,837 shares of Cytokinetics common stock. The stock price was trading near its 52-week low of $51 and had decreased by 8.6% over the previous week. Analysts view the stock as undervalued, with a Fair Value of $61.76, and six analysts have recently raised their earnings estimates.

Cytokinetics reported strong quarterly results in Q3 2026, surpassing expectations with MYQORZO treatment sales and an adjusted loss of $1.37 per share, while revenue reached $47.6 million, exceeding the forecasted $40.61 million.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in Finance & Markets

RBA to remain on hold as recession risks build

The minutes of the Reserve Bank of Australia’s (RBA) November board meeting revealed a 3–6 split vote on raising the cash rate from 4.6% to 4.85%, with three board members warning that Australia may…

  • RBA board voted 3-6 on cash rate increase
  • Majority concerned about inflation risks
  • Governor Bullock warns entrenched inflation

More from Thursday 19 November →